4 recruiting, 1 withdrawn. 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Oligometastatic Prostate Cancer (OMPC): new trials by email Literature Review of Oligometastatic Prostate Cancer (OMPC) trials Research Report on Oligometastatic Prostate Cancer (OMPC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JUR-003 in Adult Patients With Metastatic Prostate Cancer JUR-003 - Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC) | Phase 1 | Recruiting | Juri Biosciences, Inc. | 210 | 2026-09-01 | 2026-10-15 |
| HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) Stereotactic body radiotherapy (SBRT) - Prostate Cancer Metastatic Disease, Oligometastatic Prostate Cancer (OMPC) | Not applicable | Recruiting | Institut Cancerologie de l'Ouest | 18 | 2026-06-01 | 2026-06-04 |
| Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) Thermal ablation - Oligometastatic Prostate Cancer (OMPC), Prostate Cancer (Adenocarcinoma) | Withdrawn | University Hospital, Ghent | 2026-05-10 | 2026-05-13 | ||
| Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 14 | 2026-03-03 | 2026-03-11 |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg) - Oligometastatic Prostate Cancer (OMPC) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 450 | 2024-03-12 | 2026-10-21 |
Prostatic Neoplasms (2) · Adenocarcinoma (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Cryosurgery (1) · Gallium (1) · Lutetium-177 (1) · Nivolumab (1) · PSMA-11 (1) · Radiofrequency Ablation (1) · Radiosurgery (1) · Transurethral Resection of Prostate (1) · spartalizumab (1)
Institut Cancerologie de l'Ouest (1) · Juri Biosciences, Inc. (1) · Novartis Pharmaceuticals (1) · University Hospital, Ghent (1) · University of Wisconsin, Madison (1)
United States (3) · Belgium (2) · France (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · China (1) · Colombia (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1)